| CELLDEX THER. DL-,001 |
| USA |
| Gesundheit |
| US15117B2025 / A2PEAB |
| TCE2 (Frankfurt) / CLDX (NASDAQ) |
| FRA:TCE2, ETR:TCE2, TCE2:GR, NASDAQ:CLDX |
| - |
| https://www.celldex.com/ |
|
Celldex Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted immunotherapies for cancer and other serious diseases. Its research platforms leverage novel antibody the..
>Volltext.. |
| 2438.56 Mio. EUR |
| 2053.19 Mio. EUR |
| 0.76 Mio. EUR |
| -268.13 Mio. EUR |
| -248.79 Mio. EUR |
| -3.74 EUR |
| 1.67 Mio. EUR |
| 31.34 Mio. EUR |
| -194.86 Mio. EUR |
| 8.68 |
| -89.27% |
| -48.5% |
| - |
| - |
| - |
| - |
| CELLDEX |
| 22.07.26 |
|